Major Events of Qidu Pharma in 2022

1. Diyixin® - Levofloxacin Hydrochloride and Sodium Chloride Injection researched and developed independently by Qidu Pharma passes the drug consistency evaluation and is approved for marketing.

On June 16th, 2022, Diyixin® - Levofloxacin Hydrochloride and Sodium Chloride Injection, 10ml:0.25g which is the first of its kind and 20ml:0.5g, researched and developed independently by Qidu Pharma was granted drug registration certificates, and it pass the generic drug consistency evaluation.

2. 3 substantial Special API projects of API department, Qidu Pharma, is under construction.

On April 8th, 2022, construction of 3 substantial Special API projects including Levocarnitine, Lipoic, and Injectable Sodium Bicarbonate started, which was one of the core projects in 2022 listed by Shandong Government. Special APIs, active pharmaceutical ingredients for a brand-name drug which just became or nearly become an off-patent drug, have a bright future for that they are among the key classes in pharmaceutical industry encouraged by the Chinese government, and also one of the 6 key segments of Qidu Pharma. The construction has been going well since then, which indicates a new stage of APIs development of Qidu Pharma.

3. Qidu Pharma, once again among the Top 100 Enterprises in Chinese Pharmaceutical Industry.

On December 17th, 2022, the 39th China Pharmaceutical Industry Information Annual Conference 2022 was held by China National Pharmaceutical Industry Information Center. During the conference, Qidu Pharma was once again among the Top 100 Enterprises in Chinese pharmaceutical industry, which was the 9th consecutive year of obtaining this honor, and was granted the honor of the Most Valuable Company to Be Invested in. This is an affirmation by authority of the comprehensive and creative capability of Qidu Pharma, and also the result of a sustainable development as well as the widely-acknowledged brand of Qidu Pharma.